Sumatriptan. An updated review of its use in migraine

Drugs

Volumn 55, Issue 6, 1998, Pages 889-922

  Perry, Caroline M ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; DIHYDROERGOTAMINE MESILATE; LYSINE ACETYLSALICYLATE; METOCLOPRAMIDE; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN;

ABSENTEEISM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CLUSTER HEADACHE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FATIGUE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALAISE; META ANALYSIS; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOPHOBIA; QUALITY OF LIFE; RECTAL DRUG ADMINISTRATION; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPTOM; TASTE DISORDER; VOMITING;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; CEREBROVASCULAR CIRCULATION; CLUSTER HEADACHE; CORONARY CIRCULATION; DRUG INTERACTIONS; ECONOMICS, PHARMACEUTICAL; HUMANS; INJECTIONS, SUBCUTANEOUS; MIGRAINE DISORDERS; SEROTONIN AGONISTS; SUMATRIPTAN; VASOCONSTRICTOR AGENTS;

EID: 0031803892     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855060-00020     Document Type: Article

References (188)

1. Heywood J, Zagami AS. Treating acute migraine attack: guidelines for general practitioners and emergency department doctors. Curr Ther 1997; 37: 33-7
2. Goadsby PJ, Olesen J. Diagnosis and management of migraine. BMJ 1996; 312: 1279-83
3. Goadsby PJ. Diagnosis and optimum treatment of migraine. CNS Drugs 1994; 1: 245-53
4. International Headache Society (IHS). Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
5. Payne K, Kozma CM, Lawrence HJ. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine: a retrospective cost-efficacy analysis. Pharmacoeconomics 1996; 10: 59-71
6. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993; 82: 769-72
7. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47: 622-51
8. 1B/1D receptor agonists on neurogenic durai plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 1997; 36(4/5): 525-33
9. Williamson DJ, Hargreaves RJ, Hill RG, et al. Sumatriptan inhibits neurogenic vasodilation of durai Wood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia 1997; 17: 525-31
10. Bateman DN. Sumatriptan. Lancet 1993; 341: 221
11. Humphrey PPA. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurology 1991; 238: S38-44
12. 1-like receptor agonist, GR43175. Cephalalgia 1989; 9 Suppl. 9: 23-33
13. Humphrey PPA, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994; 14: 401-10
14. Tietjen G. Mechanisms of Sumatriptan. Cephalalgia 1994; 14: 393
15. Dechant KL, Clissold SP. Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of migraine and cluster headache. Drugs 1992; 43: 776-98
16. 1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia 1997; 17: 849-54
17. Wilkinson M, Pfaffenrath V, Sehoenen J, et al. Migraine and cluster headache - their management with Sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995; 15: 337-57
18. 1Dβ receptors. Eur J Pharmacol 1995; 287: 79-84
19. 1D subtypes. Naunyn Schmiedebergs Arch Pharmacol 1996; 354: 226-36
20. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202-6
21. 1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 682-8
22. Pierce PA, Xie G-X, Peroutka SJ, et al. Dual effect of the serotonin agonist, Sumatriptan, on peripheral neurogenic inflammation. Reg Anesth 1996; 21: 219-25
23. 3H]sumatriptan-binding sites in post-mortem human brain [see comments]. Cephalalgia 1996; 16: 317-22
24. 1I-receptors. Eur J Pharmacol 1996; 295: 271-4
25. Branchek TA, Zgombick JM, Bard JA, et al. How does sumalriptan really work? [abstract]. Cephalalgia 1997; 17: 396-7
26. American Hospital Formulary Service Drug Information. Sumatriptan prescribing information. American Society of Health-System Pharmacists, 1996
27. Panconesi A, Franchi G, Anselmi B, et al. Amplifying effect of sumatriptan on noradrenaline venoconstriction in migraine patients. Cephalalgia 1993; 13: 383-8
28. Ferrari MD, Haan J, Blokland JAK, et al. Cerebral blood flow during migraine attacks without aura and effect of sumatriptan. Arch Neurol 1995; 52: 135-9
29. Henkes H, May A, Kühne D, et al. Sumatriptan: vasoactive effect on human durai vessels, demonstrated by subselective angiography. Cephalalgia 1996; 16: 224-30
30. Caekebeke JFV, Ferrari MD, Zwersloot CP, et al. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology 1992; 42: 1522-6
31. Caekebeke JFV, Saxena PR, Ferrari MD. Effect of sumatriptan on cranial blood flow velocity during and between migraine attacks. In: Oleson J, Saxena PR, editors. Frontiers in Headache research: 5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press, 1992.
32. 1Dβ receptors [see comments]. Circulation 1994; 90: 1141-53
33. Van DenBrink AM, Ramrattan NR, Bax WA, et al. Human isolated coronary artery contraction to sumatriptan is inversely related to age and positively related to endothelial functional integrity [abstract]. Cephalalgia 1997; 17: 244-5
34. 1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol 1996; 42: 431-41
35. Van Den Brink AM, Bax WA, Ferrari MD, et al. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br J Pharmacol 1996; 119: 855-62
36. Ferro A, Longmore J, Hill RG, et al. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. Br J Clin Pharmacol 1995; 40:245-51
37. van Es NM, Bruning TA, Camps J, et al. Assessment of peripheral vascular effects of antimigraine drugs in humans. Cephalalgia 1995; 15: 288-91
38. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression with rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992; 106: 409-15
39. Friberg L, Olesen J, Iverson HK, et al. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 1991; 338: 13-7
40. 1 receptor agonists, sumatriptan and CP 93,129, on durai arterial flow in the rat. Fur J Pharmacol 1997; 332: 173-81
41. Panconesi A, Anselmi B, Curradi C, et al. Comparison between venoconstrictor effects of sumatriptan and ergotamine in migraine patients. Headache 1994; 34: 194-7
42. Goadsby PJ, Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia 1991; 11(11): 3-4
43. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56
44. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991: 365-71
45. Buzzi MG, Carter WB, Shimizu T, et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991; 30(11): 1193-200
46. Fuller RW. Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions. Ann N Y Acad Sci 1996; 780: 176-84
47. O'Shaughnessy CT, Connor HE. Activation of sensory nerves in guinea-pig isolated basilar artery by nicotine: evidence for inhibition of trigeminal sensory neurotransmission by sumatriptan. Eur J Pharmacol 1994; 259: 37-42
48. Evers S, Suhr B, Grotemeyer K-H. Effects of sumatriptan on visually evoked event-related potentials. In: Oleson J, Moskowitz MA, editors. Experimental headache models. Philadelphia: Lippencott-Raven, 1995: 289-292
49. Scott AK. Sumatriptan: clinical pharmacokinetics. Clin Pharmacokinet 1994; 27: 337-44
50. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995; 47(6): 543-8
51. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-4
52. Visser WH, Burggraaf J, Muller LM, et al. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 1996; 60: 452-60
53. Warner PE, Brouwer KLR, Hussey EK, et al. Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm Res 1995; 12: 138-43
54. Rani PU, Naidu MUR, Kumar TR, et al. A bioequivalence study of two brands of sumatriptan tablets. Curr Ther Res Clin Exp 1996; 57: 589-98
55. Moore KHP, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997; 17: 541-50
56. Kunka RL, Hussey EK, Shaw S, et al. Safety, tolerabilily, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Cephalalgia 1997; 17: 532-40
57. Cutler NR, Hussey EK, Sramek JJ, et al. Pharmacokinetics of oral sumatriptan in migraine patients during an attack and while painfree [abstract]. Biol Psychiatry 1992; 31: 180A
58. Dixon CM, Saynor DA, Andrew PD, et al. Disposition of sumatriptan in laboratory animals and humans. Drug Metab Dispos 1993; 21: 761-9
59. Salonen R, Ashford E, Dahlöf C, et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurology 1994; 241: 463-9
60. Gutterman DL, Plachtka JR, Donn K, et al. Evaluation of the safety and pharmacokinetic properties of single subcutaneous doses of GR43175c in healthy, adult, male volunteers. Cephalalgia 1989; 9 Suppl. 10: 412-3
61. Scott AK, Grimes S, Ng K, et al. Sumatriptan and cerebral perfusion in healthy volunteers. Br J Clin Pharmacol 1992; 33: 401-4
62. Busch MA, Plachetka JR, Donn KH, et al. Evaluation of the pharmacokinetics and safety of ascending single oral doses of GR 43175 administered to healthy male volunteers. Cephalalgia 1989; 9 Suppl. 10: 414-5
63. Schenker S, Yang YQ. Perez A, et al. Sumatriptan (Imitrex) transport by the human placenta. Proc Soc Exp Biol Med 1995; 210: 213-20
64. Wojnar-Horton RE, Hackett LP, Yapp P, et al. Distribution and excretion of sumatriptan in human milk. Br Clin Pharmacol 1996; 41: 217-21
65. Scott AK, Walley T, Breckenridge AM, et al. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol 1991; 32: 581-4
66. Van Hecken AM, Depré M, De Schepper PJ, et al. Lack of effect of flunarizine on the pharmacokinetics and pharmcodynamics of sumatriptan in healthy volunteers. Br J Clin Pharmacol 1992; 34: 82-4
67. Srinivas NR, Shyu WC, Upmalis d, et al. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and Mimatriplan succinate. J Clin Pharmacol 1995; 35: 432-7
68. Kamali F, Tommey R, Wallace RJ, et al. The safety of sumatriptan administration 2 h after subcutaneous injection of alniditan, a new anti-migraine drug, in healthy volunteers [abstract]. Br J Clin Pharmacol 1996; 41: 437P
69. Williams P, Kempsford R, Fuseau L, et al. Absence of significant pharmacodynamic or pharmacokinetic interaction with naratriptan and sumatriptan co-administration [abstract]. Cephalalgia 1997; 17: 417
70. Franklin M, Odontiadis J, Clement EM, et al. Sumatriptan in plasma by HPLC with coulometric detection: effect of paroxetine treatment on plasma sumatriptan concentrations. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 40
71. Wing Y-K, Clifford E-M, Sheehan BD, et al. Paroxetine treatment and the prolactin response to sumatriptan. Psychopharmacology 1996; 124: 377-9
72. Williams P, Fuseau E, Cosson V, et al. Sumatriptan pharmacokinetics are significantly altered by monoamine oxidase inhibitor co-administration [abstract]. Cephalalgia 1997; 17: 408
73. Solomon GD, Litaker DG, Genzen JR. Use of clinical features to predict response to sumatriptan in migraine [abstract]. Neurology 1996 Feb; 46 Suppl.: A323-324
74. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994; 44: 1587-92
75. Visser WH, Jaspers NMWH, de Vriend RHM, et al. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996; 16: 264-9
76. Blakeborough P, Lloyd DK, Arnold WSG. Speed of response to sumatriptan in migraine and cluster headache. Br J Clin Res 1994; 5: 123-38
77. Henry P, d'Allens H. Subcutaneous sumatriptan in the acme treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-LyonGrenoble. Headache 1993; 33: 432-5
78. Bousser MG, D'Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Intern Med 1993; 234: 211-6
79. Mushet GR, Cady RK, Baker CC, et al. Efficacy and tolerability of subcutaneous suniatriptan administered using the IMITREX® STATdose TM system. Clin Ther 1996; 18: 687-99
80. Boureau F, Chazot G, Emile J, et al. Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. Eur Neurol 1995; 35: 264-9
81. Schoenen J, Bulcke J, Caekebeke J, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia 1994; 14: 55-63
82. Facchinetti F, Bonellie G, Kangasniemi P, et al. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. Obstet Gynecol 1995; 86: 911-6
83. Jensen K, Tfelt-Hansen P, Hansen EW, et al. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. Cephalalgia 1995; 15: 423-9
84. Russell MB, Holm-Thomsen OH, Rishoj-Nielsen M, et al. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia 1994; 14: 241-0
85. Touchon J, Bertin L, Pilgrim AJ. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996; 47: 361-5
86. Winner P, Ricalde O, Le Force B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180-4
87. Boureau F, Chazot G, Emile J, et al. Clinical efficacy of sumatriptan and its impact on quality of life in comparison with the usual acute treatments of migraine. v. Smith-Gordon and Company. London, England: , 1994.
88. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol 1991; 31: 323-31
89. Akpunonu BE, Mutgi AB, Federman DJ, et al. Subcutaneous sumatriptan for treatment of acule migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med 1995; 25: 464-9
90. Cutler N, Mushet GR, Davis R. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995 Aug; 45 Suppl. 7: S5-9
91. Centonze V, Polito MR, Di Bari M, et al. Evaluation of the efficacy of oral sumatriptan in the therapy of acute migraine. Clin Ter 1995; 146: 721-8
92. Díez-Tejedor E, Oral Sumatriptan Spanish Trial. Assessment of response consistency to oral sumatriptan in migraine attacks [abstract]. Cephalalgia 1997; 17: 412
93. Sargent J, Kirchner JR, Davis R, et al. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995 Aug; 45 Suppl. 7: S10-14
94. Gross M, Barrie M, Bates D, et al. The efficacy of sumatriptan in menstrual migraine [abstract]. Eur J Neurol 1995 Sep; 2 Suppl. 1: 144-5
95. Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache. In press
96. Diener HC, Klein KB, for the Multinational Oral 311C90 and Sumatriptan Comparative Study Group. The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine [poster]. 3rd European Headache Conference. 1996 Jun 5-8; Sardinia
97. Göbel H, Boswell D, Winter P, et al. A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan. Cephalalgia 1997; 17: 426
98. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923-6
99. Visser WH, Terwindt GM, Reines SA. Rizatriptan vs sumatriptan in the acute treatment of migraine: a placebo-controlled, dose-ranging study. Arch Neurol 1996; 53: 1132-7
100. Dahlof C. Sumatriptan nasal spray: a review of data from multinational clinical trials. Funct Neurol 1996; 11: 150
101. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 1997; 49: 1225-30
102. Hernández-Gallego J. The efficacy and tolerability of sumatriptan 10mg and 20mg nasal sprays in the acute treatment of migraine [abstract]. Cephalalgia 1995 Suppl. 14: 240
103. Reches et al. The long-term tolerability, safety and efficacy of sumatriptan 20mg nasal spray in the acute treatment of migraine [abstract]. Cephalalgia 1995 Suppl. 14: 241
104. Massiou H et al. A comparison of sumatriptan nasal spray 20mg and intranasal dihydroergotamine in the acute treatment of migraine [poster]. 3rd European Headache Society. 1996 Jun 5-8; Sardinia, 20
105. Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 332-8
106. Rapoport AM, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs 1997; 7: 37-46
107. Diamond S, DeBussey S, Asgharnejad M. Efficacy and tolerability of sumatriptan nasal spray: a review of United States studies [abstract]. Cephalalgia 1997; 17: 418
108. Ryan R, Diamond S, DeBussey S, et al. The efficacy and tolerability of sumatriptan 5, 10, and 20mg nasal spray in the acme treatment of repeated attacks of migraine. Headache Quarterly 1997 Feb 19-23; (3): 247
109. Ashford EA. The efficacy and tolerability of sumatriptan nasal spray in selected patient subgroups [abstract]. Cephalalgia 1997; 17: 418-9
110. Tepper SI, Cochran A, Hobbs S, et al. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998; 51(1): 31-5
111. Pfaffenrath V. Headache recurrence. Cephalalgia 1996; 16: 215-6
112. Cady RK, Rubino J, Crummett D, Littlejohn TW 3rd. Oral sumatriptan in the treatment of recurrent headache. Arch Fam Med 1994; 3: 766-72
113. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994; 14: 330-8
114. Cull RE, Price WH, Dunbar A. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. J Neurol Neurosurg Psychiatry 1997; 62: 490-5
115. Ekbom K, Krabbe A, Micelli G, et al. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Cephalalgia 1995; 15: 230-6
116. Mathew NT. Long-term subcutaneous sumatriptan in cluster headache. Cephalalgia 1995; 15: 164
117. Coukell AJ, Lamb HM. Sumatriptan: a pharmacoeconomic review of its use in migraine. Pharmacoeconomics 1997; 11: 473-90
118. Osterhaus JT, Gutterman DL, Plachetko JR. Healthcare resource use and lost labour costs of migraine headache in the United States. Pharmacoeconomics 1992; 2: 67-76
119. Cull RA, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103-15
120. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993; 43 Suppl. 3: S6-10
121. Bosanquet N, Zammit-Lucia J. Migraine prevention or cure? Br J Med Econ 1992; 2: 81-91
122. Gaist D, Andersen M, Aaarup A-L, et al. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997; 43: 429-33
123. Adelman JU, Sharfman M, Johnson R. Impact of oral sumatriptman on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Man Care 1996; 2(10): 1407-16
124. Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996; 36: 137-43
125. Gross MLP, Dowson AJ, Deavy L. Impact of oral sumatriptan 50 mg on work productivity and quality of life in migraineurs. Br J Med Econ 1996; 10: 231-46
126. Cortelli P, Dahlöf C, Bouchard J, et al. A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity. Pharmacoeconomics 1997; 11 Suppl. 1: 35-42
127. Heywood J, Bouchard J, Cortelli P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. I: design, methods and clinical findings. Pharmacoeconomics 1997; 11 Suppl. 1: 11-23
128. Solomon GD, Litaker DG. The impact of drug therapy on quality of life in headache and migraine. Pharmacoeconomics 1997; 11: 334-42
129. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20: 131-7
130. Dahlöf CGH, Dimenäs E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995 Feb; 15: 31-6
131. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995; 35: 449-54
132. Edmond M, Miller DW, Clements B, et al. Impact of sumatriptan on health-related quality of life and productivity in migraineurs [abstract]. Neurology 1995 Apr; 45 Suppl. 4: S465
133. Cohen JA, Beall DG, Beck A, et al. Use of sumatriptan to treat migraines in patients in a group model HMO: health care use, health-related quality of life, and clinical effectiveness [abstract]. Neurology 1996 Feb; 46 Suppl.: A322-323
134. Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996; 28: 171-7
135. Cohen JA, Batenhorst AS, Pait DG, et al. Relationships between disease-specific quality of life scores and health-care resource use among HMO patients using sumatriptan injection for 12 months to treat migraines [abstract]. Cephalalgia 1997; 17: 429-30
136. Jhingran P, Cady RK, Rubino J, et al. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996; 42: 36-42
137. Dahlöf C, Bouchard J, Cortelli P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life. Pharmacoeconomics 1997; 11 Suppl. 1: 24-34
138. Dahlöf CGH. Health-related quality of life under six months' treatment of migraine - an open clinic-based longitudinal study. Cephalalgia 1995; 15: 414-22
139. D'allens H, Richard A, Bertin L, et al. Responsiveness assessment of a specific quality of life questionnaire for migraineurs (QVM) [abstract]. Qual Life Res 1994; 3: 72
140. Beall D, Cohen J, Miller D, et al. An interim analysis of the use of subcutaneous sumatriptan in a managed care setting: effects on health-related quality of life, impact on health care resource use, and clinical efficacy [abstract]. Pharmacotherapy 1995; 15: 385
141. Solomon G, Nielsen K, Miller DW. The effects of sumatriptan on migraineurs' health-related quality of life: a review of data from clinical trials. Headache 1995; 35: 308
142. Glaxo Laboratories. Imigran prescribing information. ABPI Compendium of Data Sheets ed. London, UK: Datapharm Publications Limited, 1997
143. Simmons VE, Blakeborough P. The safety profile of sumatriptan. Rev Contemp Pharmacother 1994; 5: 319-28
144. Lloyd K. The clinical profile of sumatriptan: safety and tolerability. Eur Neurol 1994; 34 Suppl. 2: 40-3
145. Brown EG, Endersby CA, Smith RN, et al. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991; 31: 339-44
146. Bates D. Long-term tolerability, safety and efficacy of subcutaneous suniatriptan in migraine patients. Eur J Neurol 1995 Sep; 2 Suppl. 1: 146
147. Pearce H, Shakir S, Wright S, et al. Postmarketing surveillance of sumatriptan in the treatment of acute migraine [abstract]. Pharmacoepidemiol Drug Saf 1996 Aug; 5 Suppl. 1: 86
148. Goa KL, Balfour JA. Management of acute migraine attacks: defining the role of suniatriptan. Dis Manage Health Outcomes 1997; 2(3): 141-55
149. Ottervanger JP, Valkenburg HA, Grobbee DB, et al. Characteristics and determinants of sumatriptan-associated chest pain. Arch Neurol 1997; 54: 1387-92
150. Visser WH, Jaspers NMWH, de VRHM. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996; 16: 554-9
151. Ottervanger JP, van Witser TB, Valkenburg HA, et al. Adverse reactions attributed to sumatriptan: a postmarketing study in general practice. Eur J Clin Pharmacol 1994; 47(4): 305-9
152. Ottervanger JP, van-Witsen TB, Valkenburg HA, et al. Post-marketing study of cardiovascular adverse reactions associated with sumatriptan. BMJ 1993; 307: 1185
153. Ottervanger JP, Stricker BHC. Cardiovascular adverse reactions to suniatriptan: cause for concern? CNS Drugs 1995; 3: 90-8
154. Lippolis A, Castini D, Cirino D, et al. Coronary vasospasm induced by subcutaneous suniatriptan: a case report. G Ital Cardiol 1994; 24: 883-6
155. Walton-Shirley M, Flowers K, Whiteside JH, et al. Unstable angina pectoris associated with Imitrex therapy [letter]. Cathet Cardiovasc Diagn 1995; 34: 188
156. Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache 1996; 36: 329-31
157. O'Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology 1995; 45: 2274-6
158. Kelly KM. Cardiac arrest following use of sumatriptan. Neurology 1995; 45: 1211-3
159. Ottervanger JP, Paalman HJA, Boxma GL, et al. Transmural myocardial infarction with sumatriptan. Lancet 1993; 341: 861-2
160. Evers S, Husstedt I-W, Enbergs A. Coronary angiography in migraine patient after subcutaneous sumatriptan. Lancet 1995; 345: 198
161. Chester AH, O'Neil GS, Yacoub MH. Sumatriptan and ischaemic heart disease. Lancet 1993; 341: 1419-20
162. Houghton LA, Foster JM, Whorwell PJ. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994; 344: 985-6
163. Foster JM, Houghton LA, Whorwell PJ. Sumatriptan at a therapeutic dose alters oesophageal motility [abstract]. Gut 1997; 40 Suppl. 1: A44
164. Foster JM, Houghton LA, Whorwell PJ. Further evidence that sumatriptan induced chest pain is oesophageal in origin: effect on oesophageal visceral sensation [abstract]. Gut 1997; 40 Suppl. 1: A31
165. O'Quinn S, Greensmith MJ, Ashford BA. The safety and tolerability of sumatriptan suppositories: review of clinical trial experience [abstract]. Cephalalgia 1997; 17: 412
166. Gaist D, Hallas J, Sindrup SH, et al. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996; 50: 161-5
167. Gaist D, Sindrup S, Hallas J, et al. Misuse of sumatriptan [letter]. Lancet 1994; 344: 1090
168. Gaist D, Hallas J, Sindrup SH, et al. Overuse of sumatriptan in a Danish county - a population-based prescription database study. Pharmacoepidemiol Drug Saf 1995 Aug; 4 Suppl. 1: 5
169. Catarci T, Lenzi GL, Cerbo R, et al. Sumatriptan and daily headache [letter]. J Neurol Neurosurg Psychiatry 1995; 58: 508
170. Ottervanger JP, Valkenburg HA, Grobbee DE et al. Pattern of sumatriptan use and overuse in general practice. Eur J Clin Pharmacol 1996; 50: 353-5
171. Evers S, Bauer B, Suhr B, et al. The epidemiology of sumatriptan abuse. In: Oleson J, Moskowitz MA, editors. Headache treatment: trial methodology and new drugs. Philadelphia: Lippincott-Raven, 1997: 149-152
172. Elser JM. Sumatriptan in the treatment of pediatric migraine. Clin Res 1993; 41: 729A
173. Hoerlein M, McMonigle G, Franz DN. Sumatriptan therapy of pediatric migraines [abstract]. Ann Neurol 1994; 36: 548
174. MacDonald JT. Treatment of juvenile migraine with subcutaneous sumatriptan. Headache 1994; 34: 581-2
175. Linder SL. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice. Headache 1996; 36: 419-22
176. Korsgaard AG, Odense C. The tolerability, safety and efficacy of oral sumatriptan 50mg and 100mg for the acute treatment of migraine in adolescents [abstract]. Cephalalgia 1995 Oct; 15 Suppl. 16: 99
177. Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study: do children with migraine respond to oral sumatriptan differently from adults? Neurology 1997; 48: 1100-3
178. Winner P, Prensky A, Linder S, et al. Efficacy and safety of oral sumatriptan in adolescent migraineurs [abstract]. Headache 1996; 36: 282
179. Skaer TL. Clinical presentation and treatment of migraine. Clin Ther 1996; 18: 229-45
180. Pfaffenrath V, Diener HC. Side effects and tolerability of sumatriptan (review article). Munch Med Wochenschr 1994; 136: 560-5
181. Diener HC, Brune K, derber W-D, et al. Behandlung der migräneattacke und migräneprophylaxe. Nervenheilkunde 1997; 16: 500-10
182. Solomon GD, Price KL. Burden of migraine: a review of its socioeconomic impact. Pharmacoeconomics 1997; 11 Suppl. 1: 1-10
183. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997 Mar; 48 Suppl. 3: S4-9
184. Gilkey SJ, Ramadan NM. Use of over-the-counter drugs in migraine: issues in self-medication. CNS Drugs 1996; 6: 83-9
185. Meyler WJ. Side effects of ergotamine. Cephalalgia 1996; 16: 5-10
186. Palmer KJ, Spencer CM. Zolmitriptan. CNS Drugs 1997; 7: 468-78
187. Goadsby PJ, Olesen J. Increasing the options for effective migraine management. Neurology 1997 Mar; 48 Suppl. 3: S1-3
188. Rose A. Facing migraine in the new millennium. Inpharma 1997; 1101: 3-4